Etanercept: An overview
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 49 (2) , 105-111
- https://doi.org/10.1016/mjd.2003.554
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Tuberculosis and Treatment with InfliximabNew England Journal of Medicine, 2002
- Etanercept‐induced subacute cutaneous lupus erythematosusRheumatology, 2001
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Inflammatory Skin Diseases, T Cells, and Immune SurveillanceNew England Journal of Medicine, 1999
- Cytokines in psoriasisInternational Journal of Dermatology, 1999
- Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients relationships with disease severityClinical and Experimental Dermatology, 1994
- Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesionsClinical and Experimental Immunology, 1994
- Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor .alpha. induced receptor aggregationBiochemistry, 1992
- Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.The Journal of Experimental Medicine, 1992
- A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity.The Journal of Experimental Medicine, 1991